
HER2 Negative Breast Cancer- Pipeline Insight, 2025
Description
DelveInsight’s, “HER2 Negative Breast Cancer- Pipeline Insight, 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in HER2 Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
HER2 Negative Breast Cancer: Overview
Breast cancer is the world’s most common disease in women, and is also a major factor that leads to death. It is reported that 5% of patients with breast cancer have distant metastasis at a diagnosis, and 30% of patients with early cancer subsequently experience the distant metastasis. Metastatic breast cancer cannot be completely cured; however, significant improvement in the survival period was observed consistent with the emergence of novel therapy. The purpose of the treatment for metastatic breast cancer is to prolong the survival period and improve the cancer patients’ quality of life (QOL) by managing cancer-related symptoms. To that end, not the same strategy for all patients but individual approach for each patient should be used. When a breast cancer is HER2-negative, it means that the cancerous cells do not contain high levels of the protein HER2.
There are many treatment options available for this type of breast cancer, but the outlook can vary. “HER2” stands for human epidermal growth factor receptor 2. It may refer to the HER2 gene or to the protein HER2, which the gene makes.HER2 proteins are receptors that sit on the surface of breast cells. They usually help control the growth and repair of healthy breast tissue. Most studies divide HER2-negative breast cancer into two types. Based on the presence or absence of hormone receptors on the surface of cancer cells: hormone receptor-positive (HR-positive) breast cancer, triple-negative breast cancer. When person have HER2-negative advanced (metastatic) breast cancer, treatment usually focuses on managing the disease, not curing the cancer. The goal is to help a person live longer and have a better quality of life. This type of cancer is most often treated with systemic therapy. These drugs go into the bloodstream to send treatment to cells and organs throughout the body. Hormonal therapy is often the first treatment doctor’s use for women with HER2-negative advanced breast cancer that's """"hormone receptor positive."""" Some 50%-70% of breast cancers are hormone receptor positive. That means that the hormones, like estrogen or progesterone, help the cancer grow. Hormonal or endocrine therapies help to block this process. Some drugs lower your levels of estrogen. Others stop estrogen from connecting to cancer cells so they can’t multiply. Hormonal therapies have a lower risk of serious side effects than chemotherapy. Many different chemotherapy drugs are used, either alone or in combination, to treat HER2-negative breast cancer. Targeted therapies block certain proteins or molecules that drive the growth and spread of cancer cells. Those molecules are the """"targets"""" of the drugs. There’s a lot of research into targeted therapies for cancer.
These drugs are also called precision medicine. Once diagnosed with HER2-negative advanced breast cancer, patient may also consider starting palliative care. Palliative therapies treat pain, anxiety, and other issues that can come along with cancer.
""HER2 Negative Breast Cancer- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the HER2 Negative Breast Cancer pipeline landscape is provided which includes the disease overview and HER2 Negative Breast Cancer treatment guidelines. The assessment part of the report embraces, in depth HER2 Negative Breast Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2 Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the HER2 Negative Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
HER2 Negative Breast Cancer Emerging Drugs
Further product details are provided in the report……..
HER2 Negative Breast Cancer: Therapeutic Assessment
This segment of the report provides insights about the different HER2 Negative Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:
HER2 Negative Breast Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HER2 Negative Breast Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HER2 Negative Breast Cancer drugs.
HER2 Negative Breast Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
HER2 Negative Breast Cancer: Overview
Breast cancer is the world’s most common disease in women, and is also a major factor that leads to death. It is reported that 5% of patients with breast cancer have distant metastasis at a diagnosis, and 30% of patients with early cancer subsequently experience the distant metastasis. Metastatic breast cancer cannot be completely cured; however, significant improvement in the survival period was observed consistent with the emergence of novel therapy. The purpose of the treatment for metastatic breast cancer is to prolong the survival period and improve the cancer patients’ quality of life (QOL) by managing cancer-related symptoms. To that end, not the same strategy for all patients but individual approach for each patient should be used. When a breast cancer is HER2-negative, it means that the cancerous cells do not contain high levels of the protein HER2.
There are many treatment options available for this type of breast cancer, but the outlook can vary. “HER2” stands for human epidermal growth factor receptor 2. It may refer to the HER2 gene or to the protein HER2, which the gene makes.HER2 proteins are receptors that sit on the surface of breast cells. They usually help control the growth and repair of healthy breast tissue. Most studies divide HER2-negative breast cancer into two types. Based on the presence or absence of hormone receptors on the surface of cancer cells: hormone receptor-positive (HR-positive) breast cancer, triple-negative breast cancer. When person have HER2-negative advanced (metastatic) breast cancer, treatment usually focuses on managing the disease, not curing the cancer. The goal is to help a person live longer and have a better quality of life. This type of cancer is most often treated with systemic therapy. These drugs go into the bloodstream to send treatment to cells and organs throughout the body. Hormonal therapy is often the first treatment doctor’s use for women with HER2-negative advanced breast cancer that's """"hormone receptor positive."""" Some 50%-70% of breast cancers are hormone receptor positive. That means that the hormones, like estrogen or progesterone, help the cancer grow. Hormonal or endocrine therapies help to block this process. Some drugs lower your levels of estrogen. Others stop estrogen from connecting to cancer cells so they can’t multiply. Hormonal therapies have a lower risk of serious side effects than chemotherapy. Many different chemotherapy drugs are used, either alone or in combination, to treat HER2-negative breast cancer. Targeted therapies block certain proteins or molecules that drive the growth and spread of cancer cells. Those molecules are the """"targets"""" of the drugs. There’s a lot of research into targeted therapies for cancer.
These drugs are also called precision medicine. Once diagnosed with HER2-negative advanced breast cancer, patient may also consider starting palliative care. Palliative therapies treat pain, anxiety, and other issues that can come along with cancer.
""HER2 Negative Breast Cancer- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the HER2 Negative Breast Cancer pipeline landscape is provided which includes the disease overview and HER2 Negative Breast Cancer treatment guidelines. The assessment part of the report embraces, in depth HER2 Negative Breast Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2 Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence HER2 Negative Breast Cancer R&D. The therapies under development are focused on novel approaches to treat/improve HER2 Negative Breast Cancer.
This segment of the HER2 Negative Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
HER2 Negative Breast Cancer Emerging Drugs
- Giredestrant : Genentech
- Inavolisib : Genentech
- CX-2009 : CytomX Therapeutics
- H3B 6545 : H3 Biomedicine
- RGT-419B : Regor Therapeutics
Further product details are provided in the report……..
HER2 Negative Breast Cancer: Therapeutic Assessment
This segment of the report provides insights about the different HER2 Negative Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in HER2 Negative Breast Cancer
- There are approx. 70+ key companies which are developing the therapies for HER2 Negative Breast Cancer. The companies which have their HER2 Negative Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Genentech.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
HER2 Negative Breast Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HER2 Negative Breast Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HER2 Negative Breast Cancer drugs.
HER2 Negative Breast Cancer Report Insights
- HER2 Negative Breast Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing HER2 Negative Breast Cancer drugs?
- How many HER2 Negative Breast Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of HER2 Negative Breast Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the HER2 Negative Breast Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for HER2 Negative Breast Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Genentech
- CytomX Therapeutics
- H3 Biomedicine
- Regor Therapeutics
- Immutep Limited
- Merck & Co
- Klus Pharma
- Olema Pharmaceuticals
- BeiGene
- AstraZeneca
- Janssen/Merck/GSK
- Ono Pharmaceutical
- Laekna Therapeutics
- NanoMab
- InSilico Medicine
- TYK Medicine
- Shanghai Pharmaceutical Group
- Verastem Oncology
- Allarity Therapeutics
- Shenzhen Yangli Pharmaceutical Technology
- Phoenix Molecular Designs
- Giredestrant
- Inavolisib
- CX-2009
- H3B 6545
- RGT-419B
- Runimotamab
- Eftilagimod alpha
- Ladiratuzumab vedotin
- SKB 264
- Palazestrant
- Pamiparib
- Olaparib
- Niraparib
- Ipatasertib
- ONO 4578
- Afuresertib
- NM 03 theranostic
- ISM 5043
- TY-0540
- I 022
- Tremelimumab
- Avutometinib
- Dovitinib
- TFX 06
- PMD-026
Table of Contents
180 Pages
- Introduction
- Executive Summary
- HER2 Negative Breast Cancer: Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- HER2 Negative Breast Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Giredestrant : Genentech
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- CX-2009 : CytomX Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- RGT-419B : Regor Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- HER2 Negative Breast Cancer Key Companies
- HER2 Negative Breast Cancer Key Products
- HER2 Negative Breast Cancer- Unmet Needs
- HER2 Negative Breast Cancer- Market Drivers and Barriers
- HER2 Negative Breast Cancer- Future Perspectives and Conclusion
- HER2 Negative Breast Cancer Analyst Views
- HER2 Negative Breast Cancer Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.